MC
NGEN

Moors & Cabot’s NervGen Pharma NGEN Stock Holding History

Moors & Cabot’s Portfolio NGEN Stock Details NGEN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$35.1K Buy
+17,036
New +$52.9K ﹤0.01% 951

Other funds holding NGEN

EAM
Empery Asset Management New York $86.5M AUM
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return
GCM
Ghisallo Capital Management Boston, Massachusetts $5.1B AUM 39.13% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Moors & Cabot's NGEN Position: Q2 2026 in Review

Moors & Cabot opened a new position in NervGen Pharma (NGEN) in Q2 2026: 17,036 shares worth $35.1K. The stake represents ﹤0.01% of the portfolio and ranks #951 among its holdings.

62 funds tracked by Wall St. Rank hold NGEN as of Q2 2026.

  • Moors & Cabot held 17,036 shares of NervGen Pharma worth $35.1K as of Q2 2026.
  • NervGen Pharma was a new Moors & Cabot position in Q2 2026.
  • NervGen Pharma made up ﹤0.01% of Moors & Cabot's portfolio in Q2 2026, its #951 holding.
  • 62 funds tracked by Wall St. Rank held NervGen Pharma as of Q2 2026.

Based on Moors & Cabot's 13F filing for Q2 2026, filed 10 Aug 2026.